Ekso Bionics Holdings Inc (EKSO)
Official siteMEDICAL INSTRUMENTS & SUPPLIES
Last updated: May 04, 2026 at 5:00 PM ET
Ekso Bionics Holdings Inc (EKSO) Financials: Revenue, Profit and Cash Flow
Ekso Bionics Holdings reported revenue of $12.80M for the fiscal year ended Dec 31, 2025, down 28.6% from the year before. That year, net income was -$11.70M with a net margin of -91.4%, operating cash flow was -$11.80M and free cash flow was -$11.99M. The quarter ended Mar 31, 2026 had revenue of $2.14M and net income of -$6.88M.
Revenue and Margins
The net margin was -91.4% in the fiscal year ended Dec 2025, the lowest of the 5 years shown with a net margin. Over the 9 years to Dec 2025, revenue fell from $14.22M, a compound annual decline of 1.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $12.80M | -28.6% | 53.5% | -104.1% | -91.4% |
| Dec 2024 | $17.93M | -1.9% | 53.1% | -58.4% | -63.2% |
| Dec 2023 | $18.28M | +41.6% | 49.7% | -82.7% | -83.1% |
| Dec 2022 | $12.91M | +14.8% | 48.1% | -120.5% | -116.8% |
| Dec 2021 | $11.25M | +26.6% | 60.0% | -123.0% | -86.8% |
| Dec 2020 | $8.88M | -36.2% | 57.1% | -144.8% | -178.2% |
| Dec 2019 | $13.92M | +22.8% | 48.6% | -119.6% | -87.2% |
| Dec 2018 | $11.33M | +54.1% | 38.0% | -238.5% | -238.2% |
| Dec 2017 | $7.35M | -48.3% | 28.1% | -429.9% | -396.1% |
| Dec 2016 | $14.22M | N/A | 20.7% | -194.0% | -165.0% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.80M | $17.93M | $18.28M | $12.91M | $11.25M | $8.88M | $13.92M | $11.33M | $7.35M | $14.22M |
| Cost of revenue | $5.95M | $8.41M | $9.20M | $6.70M | $4.50M | $3.81M | $7.15M | $7.02M | $5.28M | $11.27M |
| Gross profit | $6.84M | $9.51M | $9.08M | $6.21M | $6.75M | $5.07M | $6.76M | $4.31M | $2.07M | $2.95M |
| Research and development | $3.03M | $3.87M | $5.03M | $3.63M | $2.75M | $2.47M | $4.60M | $5.85M | $9.48M | $8.88M |
| Operating income | -$13.33M | -$10.46M | -$15.11M | -$15.56M | -$13.83M | -$12.86M | -$16.64M | -$27.03M | -$31.61M | -$27.59M |
| Net income | -$11.70M | -$11.33M | -$15.20M | -$15.08M | -$9.76M | -$15.82M | -$12.13M | -$26.99M | -$29.12M | -$23.47M |
| EBITDA | -$9.81M | -$9.45M | -$13.20M | -$14.04M | -$9.09M | N/A | -$11.06M | -$24.89M | -$26.74M | -$21.60M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.14M | $3.14M | $4.23M | $2.06M | $3.38M | $5.09M | $4.13M | $4.95M | $3.76M | $4.85M | $4.61M | $4.70M |
| Gross profit | $1.07M | $1.67M | $2.55M | $819.00K | $1.81M | $2.71M | $2.21M | $2.64M | $1.95M | $2.37M | $2.46M | $2.25M |
| Operating income | -$5.62M | -$4.51M | -$1.40M | -$3.98M | -$3.44M | -$2.23M | -$2.64M | -$2.33M | -$3.26M | -$3.45M | -$2.93M | -$4.28M |
| Net income | -$6.88M | -$4.67M | -$1.42M | -$2.71M | -$2.89M | -$3.41M | -$2.07M | -$2.42M | -$3.43M | -$3.21M | -$3.37M | -$4.23M |
Balance Sheet
As of Dec 2025, total debt of $2.49M exceeded cash and equivalents by $1.32M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $20.11M | $26.65M | $28.92M | $40.90M | $49.17M | $20.60M | $21.91M | $17.66M | $37.99M | $24.43M |
| Current assets | $14.05M | $18.84M | $20.21M | $31.04M | $47.80M | $18.42M | $18.81M | $14.97M | $34.94M | $20.68M |
| Cash and equivalents | $1.17M | $6.49M | $8.64M | $20.52M | $40.41M | $12.86M | $10.87M | $7.66M | $27.81M | $16.85M |
| Total liabilities | $11.08M | $13.95M | $16.31M | $15.46M | $11.95M | $16.16M | $15.12M | $14.93M | $16.60M | $17.89M |
| Short-term debt | $1.69M | $1.68M | $1.61M | $2.65M | $229.00K | $548.00K | $2.77M | $2.37M | $2.17M | $108.00K |
| Long-term debt | $798.00K | $3.85M | $4.83M | $3.77M | $1.99M | $9.11M | $407.00K | $2.65M | $4.83M | $6.79M |
| Shareholder equity | $9.03M | $12.71M | $12.61M | $25.44M | $37.22M | $4.43M | $6.80M | $2.73M | $21.39M | $6.53M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $19.67M | $20.11M | $21.66M | $23.17M | $27.31M | $26.65M | $29.21M | $26.98M | $28.96M | $28.92M | $31.18M | $33.99M |
| Total liabilities | $13.93M | $11.08M | $11.98M | $12.24M | $14.62M | $13.95M | $14.34M | $14.93M | $14.91M | $16.31M | $15.93M | $16.18M |
| Cash and equivalents | $3.99M | $1.17M | $2.72M | $5.24M | $8.05M | $6.49M | $8.29M | $5.88M | $8.80M | $8.64M | $9.94M | $13.31M |
| Shareholder equity | $2.09M | $9.03M | $9.68M | $10.93M | $12.69M | $12.71M | $14.87M | $12.06M | $14.05M | $12.61M | $15.26M | $17.81M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.80M | -$9.85M | -$12.05M | -$14.69M | -$11.16M | -$8.76M | -$15.77M | -$22.16M | -$31.23M | -$25.00M |
| Capital expenditures | $188.00K | $37.00K | $157.00K | $194.00K | $59.00K | $59.00K | $60.00K | $131.00K | $456.00K | $1.10M |
| Free cash flow | -$11.99M | -$9.88M | -$12.21M | -$14.88M | -$11.21M | -$8.81M | -$15.83M | -$22.30M | -$31.68M | -$26.09M |
| Dividends paid | $226.00K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $10.35M |
| Investing cash flow | -$188.00K | -$37.00K | -$157.00K | -$5.17M | -$59.00K | -$59.00K | -$60.00K | -$131.00K | -$456.00K | -$1.10M |
| Financing cash flow | $6.63M | $7.77M | $348.00K | $176.00K | $38.71M | $10.70M | $19.04M | $2.27M | $42.57M | $23.31M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.12M | -$4.33M | -$2.06M | -$3.44M | -$1.97M | -$1.43M | -$2.28M | -$2.67M | -$3.47M | -$1.58M | -$3.35M | -$2.90M |
| Capital expenditures | $0 | $50.00K | $50.00K | $40.00K | $10.00K | $21.00K | $8.00K | $0 | $8.00K | $43.00K | $17.00K | $55.00K |
| Free cash flow | -$2.12M | -$4.38M | -$2.11M | -$3.48M | -$1.98M | -$1.45M | -$2.29M | -$2.67M | -$3.47M | -$1.63M | -$3.37M | -$2.96M |
Frequently Asked Questions About EKSO
What is Ekso Bionics Holdings' annual revenue?
Ekso Bionics Holdings reported revenue of $12.80M for the fiscal year ended Dec 31, 2025.
How fast is Ekso Bionics Holdings' revenue growing?
Revenue was down 28.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.3%.
Is Ekso Bionics Holdings profitable?
No. Ekso Bionics Holdings reported net income of -$11.70M for the fiscal year ended Dec 31, 2025, with a net margin of -91.4%.
How much free cash flow does EKSO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$11.80M minus capital expenditures of $188.00K produced free cash flow of -$11.99M.
How much debt does Ekso Bionics Holdings have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $798.00K, short-term debt of $1.69M and cash and equivalents of $1.17M.
EKSO pages: Overview, Financials